Page last updated: 2024-09-03

sr 48692 and Ovarian Neoplasms

sr 48692 has been researched along with Ovarian Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agopiantz, M; Borghese, B; Forgez, P; Gauchotte, G; Gompel, A; Just, PA; Liu, J; Poupon, J; Ségal-Bendirdjian, E; Wu, Z	1

Trials

1 trial(s) available for sr 48692 and Ovarian Neoplasms

Article	Year
Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Nov-01, Volume: 23, Issue:21 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles; Quinolines; Receptors, Neurotensin; Xenograft Model Antitumor Assays	2017

Article

Year

Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Nov-01, Volume: 23, Issue:21

Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles; Quinolines; Receptors, Neurotensin; Xenograft Model Antitumor Assays

2017